BC Innovations | Feb 21, 2018
Distillery Therapeutics

Neurology

INDICATION: Depression Rat studies suggest inhibiting KCNJ10 in the lateral habenula could help treat depression. In a rat model of depression, astrocyte levels of KCNJ10 in the lateral habenula were higher than in normal rats....
BC Extra | Feb 14, 2018
Preclinical News

Three targets in the same brain region could alleviate depression

A Zhejiang University team published a pair of papers in Nature suggesting ketamine works by modulating the firing of neurons in the lateral habenula, a brain region that controls reward signaling. The studies point to...
BC Innovations | May 1, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Potassium channel Kir4.1 (KCNJ10) Mouse studies suggest increasing Kir4.1 expression could help treat HD. In mouse models of HD, striatal astrocytes were...
BC Innovations | Jul 26, 2012
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Potassium channel KIR4.1 (KCNJ10) Human studies suggest detecting serum antibodies against KCNJ10 could help diagnose MS. Immunoreactive assays of human serum...
Items per page:
1 - 4 of 4